Accession Number
DB06228  (DB08477)
Small Molecule

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.

  • Rivaroxaban
External IDs
BAY 59-7939 / BAY-59-7939 / JNJ-39039039 / JNJ39039039
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
XareltoTablet, film coated15 mg/1OralAvera McKennan Hospital2015-03-162018-06-11Us50458 0578 30 nlmimage10 444d2239
XareltoTablet, film coated10 mgOralBayer Ag2008-09-30Not applicableEu
XareltoTabletOralBayer2008-09-16Not applicableCanada
XareltoTablet, film coated2.5 mgOralBayer Ag2008-09-30Not applicableEu
XareltoTablet, film coated15 mgOralBayer Ag2008-09-30Not applicableEu
XareltoTablet2.5 mgOralBayer2018-09-28Not applicableCanada
XareltoTablet, film coated20 mgOralBayer Ag2008-09-30Not applicableEu
XareltoTablet, film coated10 mgOralBayer Ag2008-09-30Not applicableEu
XareltoTablet, film coated2.5 mgOralBayer Ag2008-09-30Not applicableEu
XareltoTablet, film coated20 mg/1OralJanssen Pharmaceuticals, Inc.2011-11-05Not applicableUs50458 0579 30 nlmimage10 8f1dc7fe
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
XareltoRivaroxaban (15 mg/1) + Rivaroxaban (20 mg/1)OralJanssen Pharmaceuticals, Inc.2014-09-16Not applicableUs
XareltoRivaroxaban (15 mg/1) + Rivaroxaban (20 mg/1)OralJanssen Pharmaceuticals, Inc.2014-09-16Not applicableUs
XareltoRivaroxaban (15 mg) + Rivaroxaban (20 mg)Kit; TabletOralBayer2015-11-022018-12-01Canada
XareltoRivaroxaban (15 mg) + Rivaroxaban (20 mg)Kit; TabletOralBayer2015-11-022018-12-01Canada
CAS number
Average: 435.881
Monoisotopic: 435.065569098
Chemical Formula
InChI Key



Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Due to a lack of safety studies, it is not recommended for use in those under 18 years old. Its use is also not recommended in those with severe renal impairment (<30mL/min).

Associated Conditions

Rivaroxaban is an anticoagulant which binds directly to factor Xa. Thereafter, it effectively blocks the amplification of the coagulation cascade, preventing the formation of thrombus. Rivaroxaban is a unqiue anticoagulant for two reasons. First of all, it is does not involve antithrombin III (ATIII) to exert its anticoagulant effects. Secondly, it is an oral agent whereas the widely used unfractionated heparin and low molecular weight heparins are for parenteral use only. Although the activated partial thromboplastin time (aPTT) and HepTest (a test developed to assay low molecular weight heparins) are prolonged in a dose-dependant manner, neither test is recommended for the assessment of the pharmacodynamic effects of rivaroxaban. Anti-Xa activity and inhibition of anti-Xa activity monitoring is also not recommended despite being influenced by rivaroxaban.

Mechanism of action

Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which is the loose meshwork that completes the clotting process. Since one molecule of factor Xa can generate more than 1000 molecules of thrombin, selective inhibitors of factor Xa are profoundly useful in terminating the amplification of thrombin generation. The action of rivaroxaban is irreversible.

ACoagulation factor X
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Following oral administration, rivaroxaban is rapidly absorbed and reaches peak plasma concentration in 2-4 hours. Bioavailability of the 10 mg dose is >80%. However, the 15-20 mg dose have a lower bioavailability if taken in the fasted state and consequently should be taken with food.

Volume of distribution

The steady state Vd is 50 L

Protein binding

Plasma protein binding is about 92% to 95%


Approximately two-thirds of the dose is metabolized. It is metabolized by CYP3A4, CYP3A5, CYP2J2 and CYP-independant mechanisms

Route of elimination

Approximately two-thirds of rivaroxaban is excreted into urine (via active tubular secretion in which approximately 36% as unchanged drug and 30% as inactive metabolism). The remaining third of the administered dose is excreted via feces in which 7% is in the form of unchanged drug and 21% as inactive metabolites.

Half life

The terminal half life is 5-9 hours in adults and 11-13 hours in the elderly.


Systemic clearance is approximately 10 L/h, so rivaroxaban is considered a drug with low clearance. Renal clearance is ~3-4 L/h.


Excessive bleeding. Overdosages should be treated using activated charcoal and supportive measures such as mechanical compression and hemodynamic support. If bleeding is not controlled, the following procoagulants can be administered: activated prothrombin complex concentrate, prothrombin complex concentrate and recombinant factor VIIa. There is also a higher chance of post procedural hemorrhage compared to enoxaparin (1.55% vs. 1.39% respectively).

Affected organisms
  • Humans and other mammals
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
(1,2,6,7-3H)Testosterone(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Rivaroxaban.
(R)-warfarin(R)-warfarin may increase the anticoagulant activities of Rivaroxaban.
(S)-Warfarin(S)-Warfarin may increase the anticoagulant activities of Rivaroxaban.
1-Testosterone1-Testosterone may increase the anticoagulant activities of Rivaroxaban.
18-methyl-19-nortestosterone18-methyl-19-nortestosterone may increase the anticoagulant activities of Rivaroxaban.
3,5-Diiodotyrosine3,5-Diiodotyrosine may increase the anticoagulant activities of Rivaroxaban.
4-hydroxycoumarin4-hydroxycoumarin may increase the anticoagulant activities of Rivaroxaban.
4-Hydroxytestosterone4-Hydroxytestosterone may increase the anticoagulant activities of Rivaroxaban.
5beta-dihydrotestosterone5beta-dihydrotestosterone may increase the anticoagulant activities of Rivaroxaban.
6-Deoxyerythronolide BThe metabolism of Rivaroxaban can be decreased when combined with 6-Deoxyerythronolide B.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include horseradish, ginkgo, ginger, garlic, and feverfew.
  • Avoid St. John's Wort. Co-administration will decrease levels of this medication.
  • Take with food. Co-administration with food increases bioavailability.


Synthesis Reference

Prabhudas BODHURI, Gamini Weeratunga, "PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF." U.S. Patent US20100273790, issued October 28, 2010.

General References
  1. Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM: Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs. 2008 Jun;17(6):925-37. doi: 10.1517/13543784.17.6.925 . [PubMed:18491993]
  2. Alban S: Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des. 2008;14(12):1152-75. [PubMed:18473863]
  3. Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E: Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. [PubMed:19846028]
  4. Imberti D, Dall'Asta C, Pierfranceschi MG: Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med. 2009 Dec;4(6):471-7. doi: 10.1007/s11739-009-0293-9. [PubMed:19696978]
  5. Alexander D, Jeremias A: Rivaroxaban in the contemporary treatment of acute coronary syndromes. Expert Opin Investig Drugs. 2011 Jun;20(6):849-57. doi: 10.1517/13543784.2011.580274. Epub 2011 May 10. [PubMed:21554163]
  6. Cabral KP: Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40. doi: 10.1007/s11239-013-0929-5. [PubMed:23645472]
External Links
PubChem Compound
PubChem Substance
PDBe Ligand
RxList Drug Page Drug Page
ATC Codes
B01AF01 — Rivaroxaban
AHFS Codes
  • 20:12.04.14 — Direct Factor Xa Inhibitors
PDB Entries
2w26 / 5vof
FDA label
Download (537 KB)
Download (480 KB)

Clinical Trials

Clinical Trials
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailablePediatrics / Thrombosis, Venous1
1CompletedNot AvailablePharmacokinetics1
1CompletedNot AvailableTherapeutic Equivalency1
1CompletedNot AvailableThrombosis, Venous1
1CompletedOtherBiological Availability1
1CompletedOtherDrug-drug Interaction Study1
1CompletedOtherHealthy Volunteers2
1CompletedOtherThrombotic events1
1CompletedPreventionProphylaxis of Venous Thromboembolic Events2
1CompletedTreatmentBioavailability / Healthy Volunteers / Pharmacokinetics1
1CompletedTreatmentEmbolism, Atrial Fibrillation and Venous Thrombosis2
1CompletedTreatmentEnd Stage Renal Disease (ESRD) / End-Stage Renal Disease (ESRD)1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentHealthy Volunteers / Impaired kidney function1
1CompletedTreatmentThrombotic events1
1RecruitingOtherHealthy Volunteers1
1RecruitingTreatmentObesity, Morbid / Post-gastrointestinal bypass surgery1
1TerminatedTreatmentGastric Bypass Status1
1, 2CompletedOtherThromboembolism1
1, 2CompletedPreventionNeoplasms1
1, 2RecruitingTreatmentCerebral Venous Thrombosis1
2Active Not RecruitingTreatmentValvular Heart Disease1
2CompletedPreventionAtrial Fibrillation (AF)3
2CompletedPreventionCardiovascular Disease, Coronary Artery Disease1
2CompletedPreventionCritical Limb Ischemia (CLI)1
2CompletedPreventionPrevention / Thromboembolism1
2CompletedPreventionProphylaxis of Venous Thromboembolic Events1
2CompletedPreventionVenous Thromboembolism4
2CompletedTreatmentAcute Coronary Syndromes (ACS)2
2CompletedTreatmentDeep Vein Thrombosis / Thrombosis, Venous2
2CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentStroke, Ischemic / Transient Ischaemic Attack (TIA)1
2CompletedTreatmentThrombosis, Venous1
2CompletedTreatmentVenous Thromboembolism2
2Enrolling by InvitationTreatmentSickle Cell Anemia / Sickle Cell-Beta0-Thalassemia / Sickle Cell-beta^0^-Thalassemia1
2Not Yet RecruitingTreatmentAnticoagulant-induced Bleeding1
2RecruitingPreventionPost-gastrointestinal bypass surgery1
2RecruitingTreatmentAmpulla of Vater Cancer / Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer) / Cancer-associated Thrombosis / Duodenal Cancer / Esophageal Cancers / Esophagogastric Junction Cancer / Hepatobiliary Cancers / Hepatocellular,Carcinoma / Malignant Gastrointestinal Stromal Tumor / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach1
2RecruitingTreatmentCerebral Venous Thrombosis1
2TerminatedTreatmentAnticoagulants / Aortic Valve Disorder / Heart Valve Prosthesis Implantation1
2Unknown StatusPreventionHemorrhage / Venous Thromboembolism1
2, 3CompletedTreatmentAtrial Appendage / Atrial Fibrillation (AF) / Hemorrhage1
2, 3Not Yet RecruitingPreventionPrevention / Stroke1
2, 3Not Yet RecruitingTreatmentAntiphospholipid Syndrome1
2, 3RecruitingTreatmentAnticoagulants and Bleeding Disorders / Prostheses and Implants / Stroke / Valve Heart Disease1
2, 3RecruitingTreatmentMenstruation / Venous Thromboembolism1
2, 3RecruitingTreatmentMultiple Myeloma in Relapse / Multiple Myeloma Progression / Multiple Myeloma Stage I / Multiple Myeloma Stage II / Multiple Myeloma Stage III / Multiple Myeloma With Failed Remission1
2, 3Unknown StatusTreatmentStroke, Ischemic / Transient Ischaemic Attack (TIA)1
3Active Not RecruitingPreventionAtrial Fibrillation (AF) / Bleeding / Stroke1
3Active Not RecruitingPreventionPrevention & Control1
3Active Not RecruitingPreventionThrombotic events1
3Active Not RecruitingTreatmentType 2 Diabetic Patients1
3CompletedDiagnosticAortic Valve Stenosis / Cardiovascular Heart Disease / Heart Valve Diseases / Thrombotic events / Ventricular Outflow Obstruction1
3CompletedPreventionArthritis / Knee Osteoarthritis (Knee OA) / Osteoarthritis, Hip / Thromboembolism1
3CompletedPreventionAtrial Fibrillation (AF)2
3CompletedPreventionAtrial Fibrillation (AF) / Stroke / Systemic Embolism1
3CompletedPreventionAtrial Septal Aneurysm / Migraine / Patent Foramen Ovale (PFO) / Stroke, Ischemic1
3CompletedPreventionHeart Failure / Infectious Diseases / Respiratory Insufficiency / Rheumatic Diseases / Stroke, Acute1
3CompletedPreventionMalignancies / Neoplasms1
3CompletedPreventionPeripheral Artery Disease (PAD)1
3CompletedPreventionPrevention / Venous Thromboembolism1
3CompletedPreventionPulmonary Embolism / Thromboembolism / Thrombosis, Venous / Thrombotic events / Venous Thromboembolism1
3CompletedPreventionVenous Thromboembolism7
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Myocardial Infarction / Myocardial Ischemia / Unstable Angina Pectoris1
3CompletedTreatmentAntiphospholipid Syndrome1
3CompletedTreatmentAtrial Fibrillation (AF)2
3CompletedTreatmentAtrial Fibrillation (AF) / Percutaneous Coronary Intervention (PCI)1
3CompletedTreatmentChronic Portal Vein Thrombosis / Deep Vein Thrombosis1
3CompletedTreatmentCoronary Artery Disease / Heart Failure1
3CompletedTreatmentDeep Vein Thrombosis1
3CompletedTreatmentDeep Venous Thrombosis1
3CompletedTreatmentNeoplasms / Venous Thromboembolism1
3CompletedTreatmentPrevention / Venous Thromboembolism1
3CompletedTreatmentPulmonary Embolism2
3CompletedTreatmentSuperficial Vein Thrombosis1
3CompletedTreatmentSymptomatic Superficial Vein Thrombosis1
3CompletedTreatmentThrombosis, Venous1
3CompletedTreatmentVenous Thromboembolism2
3Enrolling by InvitationPreventionDeep Vein Thrombosis / Surgery--Complications1
3Not Yet RecruitingPreventionLeft Ventricular Thrombus / ST Segment Elevation Myocardial Infarction (STEMI)1
3Not Yet RecruitingPreventionRheumatic Heart Disease1
3Not Yet RecruitingPreventionStroke, Ischemic1
3Not Yet RecruitingPreventionVenous Thromboembolism1
3Not Yet RecruitingTreatmentAtrial Fibrillation (AF)1
3Not Yet RecruitingTreatmentBleeding Post Cardiac Surgery / Indication for Anticoagulation1
3Not Yet RecruitingTreatmentCardiovascular Heart Disease / Chronic Kidney Disease (CKD) / End-Stage Kidney Disease1
3Not Yet RecruitingTreatmentCoronary Artery Disease / Saphenous Vein Graft Patency1
3Not Yet RecruitingTreatmentIliac Vein Compression Syndrome1
3Not Yet RecruitingTreatmentIntracranial Atherosclerotic Disease / Stroke, Ischemic1
3Not Yet RecruitingTreatmentMalignancies / Rivaroxaban / Thromboprophylaxis1
3Not Yet RecruitingTreatmentVenous Thromboembolism1
3RecruitingPreventionAcute Coronary Syndromes (ACS) / Atrial Fibrillation (AF)1
3RecruitingPreventionAtrial Fibrillation (AF)1
3RecruitingPreventionAtrial Fibrillation (AF) / Cerebral Hemorrhage1
3RecruitingPreventionAtrial Fibrillation (AF) / Flutter, Atrial / Intracranial Hemorrhage, Hypertensive / Intracranial Hemorrhages / Intraventricular Hemorrhage / Microhaemorrhage / Small Vessel Cerebrovascular Disease / Subarachnoid Hemorrhage / Subdural haematoma1
3RecruitingPreventionAtrial Fibrillation (AF) / Stroke1
3RecruitingPreventionCentral Venous Catheter Thrombosis / Malignancies / Upper Extremity Deep Vein Thrombosis1
3RecruitingPreventionPrevention of Venous Thromboembolism1
3RecruitingPreventionRadial Artery Occlusion1
3RecruitingPreventionRheumatic Heart Disease1
3RecruitingTreatmentAnticoagulant Adverse Reaction / Atrial Fibrillation (AF) / Mitral Valve Stenosis / Rheumatic Heart Disease1
3RecruitingTreatmentDeep Vein Thrombosis1
3RecruitingTreatmentLeft Ventricular Thrombus / ST Segment Elevation Myocardial Infarction (STEMI)1
3RecruitingTreatmentLiver Cirrhosis1
3RecruitingTreatmentMalignancies / Venous Thromboembolism1
3RecruitingTreatmentMesenteric Vein Thrombosis / Portal Vein Thrombosis / Splenic Vein Thrombosis1
3RecruitingTreatmentPortal Vein Thrombosis1
3RecruitingTreatmentImpaired kidney function1
3TerminatedPreventionNon-major Orthopaedic Surgery1
3TerminatedPreventionTranscatheter Aortic Valve Replacement1
3TerminatedTreatmentAntiphospholipid Syndrome1
3TerminatedTreatmentHeparin Induced Thrombocytopenia (HIT)1
4Active Not RecruitingBasic ScienceAtrial Fibrillation or Pulmonary Embolism / Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location / Need of Long Term Oral Anticoagulation Therapy (OAT)1
4Active Not RecruitingPreventionCalcifications, Vascular1
4CompletedBasic ScienceAcute Coronary Syndromes (ACS) / Atrial Fibrillation (AF)1
4CompletedBasic ScienceVenous Thromboembolism1
4CompletedOtherAntiphospholipid Antibody Syndrome1
4CompletedPreventionAtrial Fibrillation (AF)1
4CompletedPreventionCalcifications, Vascular1
4CompletedPreventionFemur Head Necrosis / Fracture of Neck of Femur / Osteoarthritis, Hip1
4CompletedPreventionKnee Osteoarthritis (Knee OA)1
4CompletedTreatmentAnticoagulating Treatment on a Duration at Least 12-month-old Superior / Anticoagulation Treatment at Least > or = to 12-month / Permanent Atrial Fibrillation / Pulmonary Embolism / Thrombosis, Venous1
4CompletedTreatmentAtrial Fibrillation (AF) / Bleeding / Stroke / Thrombo-embolism1
4CompletedTreatmentBleeding / Cancer-associated Thrombosis / Recurrences / Rivaroxaban1
4CompletedTreatmentCentral Venous Catheter Thrombosis / Neoplasms1
4CompletedTreatmentChronic Renal Failure (CRF)1
4CompletedTreatmentDeep Vein Thrombosis / Post Thrombotic Syndrome1
4CompletedTreatmentPulmonary Embolism1
4CompletedTreatmentVenous Thromboembolism1
4Not Yet RecruitingPreventionAtrial Fibrillation (AF) / Stroke1
4Not Yet RecruitingPreventionKnee Osteoarthritis (Knee OA)2
4Not Yet RecruitingPreventionLeft Atrial Appendage Thrombosis / Stroke / Thrombi1
4Not Yet RecruitingPreventionPatients With Tumor / Prophylactic Anticoagulation / Venous Thrombosis Due to Central Venous Access Device (Disorder)1
4Not Yet RecruitingSupportive CareNonvalvular Atrial Fibrillation1
4Not Yet RecruitingTreatmentAcute Coronary Syndromes (ACS) / Atrial Fibrillation (AF)1
4Not Yet RecruitingTreatmentAnticoagulant-induced Bleeding / Bleeding / Cardiovascular Heart Disease / Chronic Lung Diseases / Embolism and Thrombosis / Pulmonary Embolism / Respiratory Tract Diseases / Systemic Embolism / Venous Thromboembolism1
4Not Yet RecruitingTreatmentAtrial Fibrillation (AF) / Ischemic Heart Disease1
4Not Yet RecruitingTreatmentPeripheral Artery Disease (PAD)1
4RecruitingOtherCoronary Artery Disease / Peripheral Artery Disease (PAD)1
4RecruitingPreventionAortic Valve Insufficiency / Aortic Valve Stenosis / Thrombotic events1
4RecruitingPreventionAtrial Fibrillation (AF)2
4RecruitingPreventionAtrial Fibrillation (AF) / Stroke1
4RecruitingPreventionBleeding / Left Atrial Appendage Closure / Stroke / Thrombotic events / Transient Ischaemic Attack (TIA)1
4RecruitingPreventionDeep Vein Thrombosis / Venous Thromboembolism1
4RecruitingSupportive CarePulmonary Embolism / Thrombosis, Venous1
4RecruitingTreatmentAcute Coronary Syndromes (ACS)1
4RecruitingTreatmentAcute Coronary Syndromes (ACS) / Myocardial Infarction / Myocardial Ischemia / Unstable Angina Pectoris1
4RecruitingTreatmentAcute Heart Failure (AHF)1
4RecruitingTreatmentAtrial Fibrillation (AF)3
4RecruitingTreatmentAtrial Fibrillation (AF) / Coronary Artery Disease / Peripheral Arterial Disease (PAD)1
4RecruitingTreatmentCerebral Infarctions / Transient Ischaemic Attack (TIA)1
4RecruitingTreatmentCoronary Artery Disease1
4RecruitingTreatmentDeep Vein Thrombosis / Pulmonary Embolism1
4RecruitingTreatmentVenous Thromboembolism1
4TerminatedTreatmentPulmonary Embolism / Thrombosis, Venous1
4TerminatedTreatmentVenous Thromboembolism1
4Unknown StatusNot AvailableAnticoagulant Overdosage / Anticoagulant-induced Bleeding / Hemorrhage / Thrombotic events1
4Unknown StatusTreatmentAtrial Fibrillation (AF)1
4WithdrawnOtherSpinal Cord Injuries (SCI) / Thromboembolism1
4WithdrawnTreatmentAtrial Fibrillation (AF) / Mitral Valve Stenosis1
4WithdrawnTreatmentComplications; Arthroplasty1
4WithdrawnTreatmentCoronary Heart Disease (CHD) / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / ST Elevation Myocardial Infarction (STEMI) / Stable Angina (SA) / Unstable Angina Pectoris1
Not AvailableActive Not RecruitingNot AvailableAcute Coronary Syndromes (ACS) / Atrial Fibrillation (AF) / Pulmonary Embolism / Thrombosis, Venous1
Not AvailableActive Not RecruitingNot AvailableAnticoagulation1
Not AvailableActive Not RecruitingNot AvailableAtrial Fibrillation (AF)5
Not AvailableActive Not RecruitingNot AvailableHeart Failure1
Not AvailableActive Not RecruitingNot AvailableVenous Thromboembolism1
Not AvailableActive Not RecruitingHealth Services ResearchNeoplasms / Thrombosis, Venous1
Not AvailableActive Not RecruitingSupportive CareAtrial Fibrillation (AF) / Hemorrhage / Periodontal Diseases1
Not AvailableCompletedNot AvailableAcute Coronary Syndromes (ACS) / Atrial Fibrillation (AF) / Pulmonary Embolism / Thrombosis, Venous3
Not AvailableCompletedNot AvailableAnticoagulation1
Not AvailableCompletedNot AvailableArthroplasty, Replacement, Hip / Arthroplasty, Replacement, Knee1
Not AvailableCompletedNot AvailableAtrial Fibrillation (AF)24
Not AvailableCompletedNot AvailableAtrial Fibrillation (AF) / Death / Major Bleeding / Myocardial Infarction / Stroke, Ischemic / Systemic Embolization2
Not AvailableCompletedNot AvailableAtrial Fibrillation (Prevention of Stroke)1
Not AvailableCompletedNot AvailableBlood Clots1
Not AvailableCompletedNot AvailableDeep Vein Thrombosis / Deep Vein Thrombosis (DVT) and / or Pulmonary Embolism (PE) / Pulmonary Embolism / Venous Thromboembolism1
Not AvailableCompletedNot AvailableDeep Vein Thrombosis / Thrombosis, Venous1
Not AvailableCompletedNot AvailableIschemia, Brain1
Not AvailableCompletedNot AvailableIschemia, Brain / Non-valvular Atrial Fibrillation (NVAF)1
Not AvailableCompletedNot AvailableMajor Bleeding / Venous Thromboembolism1
Not AvailableCompletedNot AvailableNonvalvular Atrial Fibrillation1
Not AvailableCompletedNot AvailableStroke2
Not AvailableCompletedNot AvailableStroke, Ischemic1
Not AvailableCompletedNot AvailableThrombosis, Venous2
Not AvailableCompletedNot AvailableUnsuspected Pulmonary Embolism1
Not AvailableCompletedNot AvailableVenous Thromboembolism3
Not AvailableCompletedNot AvailableVenous Thrombosis and Pulmonary Embolism1
Not AvailableCompletedSupportive CareNon-valvular Atrial Fibrillation (NVAF)1
Not AvailableCompletedTreatmentPortal Vein Thrombosis1
Not AvailableEnrolling by InvitationNot AvailableDeep Venous Thrombosis / Pulmonary Embolism1
Not AvailableNo Longer AvailableNot AvailableProsthesis; Cardiac, Heart, Functional Disturbance as Result / Thromboembolism1
Not AvailableNot Yet RecruitingNot AvailableAnticoagulants Causing Adverse Effects in Therapeutic Use / Antiphospholipid Syndrome / Thrombotic events1
Not AvailableNot Yet RecruitingNot AvailableAnticoagulant / Cerebrovascular Stroke / Intracranial Hemorrhages / Matrix Metalloproteinases1
Not AvailableNot Yet RecruitingNot AvailableAtrial Fibrillation (AF)2
Not AvailableNot Yet RecruitingNot AvailableAtrial Fibrillation (AF) / Elderly / Impaired kidney function / Rivaroxaban1
Not AvailableNot Yet RecruitingNot AvailableCerebral Vein Thrombosis / Ovarian vein thrombosis / Renal Vein Thrombosis / Retinal Vein Thrombosis / Splanchnic Vein Thrombosis1
Not AvailableNot Yet RecruitingNot AvailableCoronary Artery Disease / Peripheral Artery Disease(PAD)1
Not AvailableNot Yet RecruitingNot AvailableNon-valvular Atrial Fibrillation (NVAF)1
Not AvailableNot Yet RecruitingNot AvailablePeripheral Arterial Disease (PAD)1
Not AvailableNot Yet RecruitingTreatmentAcute Exacerbation Copd / Venous Thromboembolism1
Not AvailableNot Yet RecruitingTreatmentAtrial Fibrillation (AF) / Left Atrial Appendage Thrombosis / Rivaroxaban1
Not AvailableRecruitingNot AvailableAnticoagulants and Bleeding Disorders / Venous Thromboembolism1
Not AvailableRecruitingNot AvailableAtherosclerosis1
Not AvailableRecruitingNot AvailableAtrial Fibrillation (AF)1
Not AvailableRecruitingNot AvailableAtrial Fibrillation (AF) / Coronary Artery Disease / Haemorrhage foetal / Stroke1
Not AvailableRecruitingNot AvailableAtrial Fibrillation (AF) / Recurrent Venous Thromboembolism1
Not AvailableRecruitingNot AvailableMyeloproliferative Neoplasms1
Not AvailableRecruitingNot AvailableNon-valvular Atrial Fibrillation (NVAF)3
Not AvailableRecruitingNot AvailablePulmonary Embolism1
Not AvailableRecruitingNot AvailableVenous Thromboembolism1
Not AvailableRecruitingPreventionAtrial Fibrillation (AF) / Stroke1
Not AvailableRecruitingTreatmentAcute DVT of Lower Extremity1
Not AvailableRecruitingTreatmentAtrial Fibrillation (AF) / Stroke, Acute1
Not AvailableRecruitingTreatmentBlood Clots / Deep Vein Thrombosis / Malignancies / Pulmonary Embolism / Venous Thromboembolism1
Not AvailableRecruitingTreatmentDeep Venous Thrombosis1
Not AvailableRecruitingTreatmentIschaemic Stroke / Stroke, Ischemic1
Not AvailableTerminatedNot AvailableNon-valvular Atrial Fibrillation (NVAF)1
Not AvailableUnknown StatusNot AvailableStroke, Ischemic1
Not AvailableUnknown StatusSupportive CareBlood Loss / Osteoarthritis, Hip1
Not AvailableUnknown StatusTreatmentIleofemoral Deep Vein Thrombosis1
Not AvailableWithdrawnNot AvailableKnee Replacement Surgery / Prophylaxis of Venous Thromboembolic Events / Total Hip Replacement1


Not Available
Not Available
Dosage forms
Kit; tabletOral
TabletOral2.5 mg
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral10 mg
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral15 mg
Tablet, film coatedOral2.5 mg
Tablet, film coatedOral2.5 mg/1
Tablet, film coatedOral20 mg
Tablet, film coatedOral20 mg/1
Not Available
Patent NumberPediatric ExtensionApprovedExpires (estimated)
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more


Experimental Properties
Not Available
Predicted Properties
Water Solubility0.01 mg/mLALOGPS
pKa (Strongest Acidic)13.6ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area88.18 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity104.74 m3·mol-1ChemAxon
Polarizability43.41 Å3ChemAxon
Number of Rings4ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9462
Caco-2 permeable+0.6822
P-glycoprotein substrateNon-substrate0.5691
P-glycoprotein inhibitor IInhibitor0.6325
P-glycoprotein inhibitor IIInhibitor0.5601
Renal organic cation transporterNon-inhibitor0.7562
CYP450 2C9 substrateNon-substrate0.7866
CYP450 2D6 substrateNon-substrate0.8761
CYP450 3A4 substrateSubstrate0.5964
CYP450 1A2 substrateNon-inhibitor0.6469
CYP450 2C9 inhibitorNon-inhibitor0.7035
CYP450 2D6 inhibitorNon-inhibitor0.7516
CYP450 2C19 inhibitorInhibitor0.6475
CYP450 3A4 inhibitorNon-inhibitor0.6667
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7463
Ames testNon AMES toxic0.6162
BiodegradationNot ready biodegradable0.9844
Rat acute toxicity2.4353 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8938
hERG inhibition (predictor II)Inhibitor0.6205
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)


Mass Spec (NIST)
Not Available
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available


This compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.
Organic compounds
Super Class
Organoheterocyclic compounds
Sub Class
Direct Parent
Alternative Parents
Thiophene carboxamides / 2-heteroaryl carboxamides / 2,5-disubstituted thiophenes / Oxazolidinones / Aryl chlorides / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Carbamate esters / Heteroaromatic compounds / Secondary carboxylic acid amides
show 11 more
Phenylmorpholine / 2-heteroaryl carboxamide / Thiophene carboxamide / Thiophene carboxylic acid or derivatives / 2,5-disubstituted thiophene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Oxazolidinone / Benzenoid
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid amide, organochlorine compound, thiophenes, lactam, aromatic amide, morpholines, oxazolidinone (CHEBI:68579)


1. Coagulation factor X
Pharmacological action
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
Uniprot ID
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da
  1. Melillo SN, Scanlon JV, Exter BP, Steinberg M, Jarvis CI: Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery. Ann Pharmacother. 2010 Jun;44(6):1061-71. doi: 10.1345/aph.1M681. Epub 2010 Apr 27. [PubMed:20424181]
  2. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]


Pharmacological action
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
Uniprot ID
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
  1. Mismetti P, Laporte S: [Rivaroxaban: clinical pharmacology]. Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S16-21. doi: 10.1016/S0750-7658(08)75142-6. [PubMed:19185782]
  2. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071]
Pharmacological action
General Function
Steroid hydroxylase activity
Specific Function
This enzyme metabolizes arachidonic acid predominantly via a NADPH-dependent olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids. One of the predominant enzymes responsible f...
Gene Name
Uniprot ID
Uniprot Name
Cytochrome P450 2J2
Molecular Weight
57610.165 Da
  1. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071]
Pharmacological action
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
Uniprot ID
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
  1. Cabral KP: Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40. doi: 10.1007/s11239-013-0929-5. [PubMed:23645472]


Pharmacological action
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
Uniprot ID
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
  1. Walenga JM, Adiguzel C: Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010 Jun;64(7):956-67. doi: 10.1111/j.1742-1241.2009.02286.x. [PubMed:20584229]
  2. Chen T, Lam S: Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism. Cardiol Rev. 2009 Jul-Aug;17(4):192-7. doi: 10.1097/CRD.0b013e3181aa2154. [PubMed:19525681]
  3. Xarelto FDA [File]
Pharmacological action
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
Uniprot ID
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
  1. Mueck W, Kubitza D, Becka M: Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013 Sep;76(3):455-66. doi: 10.1111/bcp.12075. [PubMed:23305158]
  2. Xarelto FDA [File]

Drug created on March 19, 2008 10:18 / Updated on April 09, 2020 22:31

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.